Merck Acquires Modifi And Preclinical Assets For GBM, Other Cancers
The deal, potentially worth more than $1.3bn, includes Modifi’s MGMT-targeting technology, which it hopes can provide a biomarker-based approach for glioblastoma multiforme.
The deal, potentially worth more than $1.3bn, includes Modifi’s MGMT-targeting technology, which it hopes can provide a biomarker-based approach for glioblastoma multiforme.